Literature DB >> 9835530

In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.

L Martínez-Martínez1, A Pascual, A I Suárez, E J Perea.   

Abstract

The in vitro activity of ketolide HMR 3647 against coryneform bacteria isolated from clinical samples was evaluated. Except against Corynebacterium jeikeium and C. urealyticum, HMR 3647 showed high activity against Corynebacterium spp., being more active than 14- and 16-membered macrolides, azithromycin, or clindamycin. HMR 3647 also had high in vitro activity against Brevibacterium spp. and Listeria monocytogenes.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9835530      PMCID： PMC106038     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics.

Authors:  A Philippon; F Bimet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  In vitro activity of 79 antimicrobial agents against Corynebacterium group D2.

Authors:  J A García-Rodriguez; J E García Sánchez; J L Muñoz Bellido; T Nebreda Mayoral; E García Sánchez; I García García
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

3.  Species identities and antimicrobial susceptibilities of corynebacteria isolated from various clinical sources.

Authors:  P Riegel; R Ruimy; R Christen; H Monteil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

4.  Antimicrobial susceptibility pattern of Corynebacterium striatum.

Authors:  L Martínez-Martínez; A Pascual; K Bernard; A I Suárez
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Most Corynebacterium xerosis strains identified in the routine clinical laboratory correspond to Corynebacterium amycolatum.

Authors:  G Funke; P A Lawson; K A Bernard; M D Collins
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 6.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

7.  Antimicrobial susceptibility patterns of some recently established coryneform bacteria.

Authors:  G Funke; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Antimicrobial activity of RU-66647, a new ketolide.

Authors:  R N Jones; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  1997 Jan-Feb       Impact factor: 2.803

9.  Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents.

Authors:  F Soriano; J Zapardiel; E Nieto
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

10.  Susceptibility of urinary isolates of Corynebacterium group D2 to fifteen antimicrobials and acetohydroxamic acid.

Authors:  F Soriano; C Ponte; M Santamaría; A Torres; R Fernández-Roblas
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790
  10 in total
  5 in total

1.  Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.

Authors:  E J Goldstein; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.

Authors:  L Martínez-Martínez; P Joyanes; A I Suárez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 3.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.

Authors:  Carlos Salas; Jorge Calvo; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

5.  Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.

Authors:  María del Carmen Conejo; Luis Martínez-Martínez; Alvaro Pascual; Ana Isabel Suárez; Evelio J Perea
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.